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of cortisol, cortisone, tetrahydrocortisol, allo-tetrahydro-
cortisol and tetrahydrocortisone was developed and vali-
dated in an LC coupled with the new detector aB Sciex 
Qtrap® 4500 tandem mass spectrometer. the steroids were 
extracted from 1 mL urine, using cortisol-D4 as internal 
standard. the quantification range was 0.1–120 ng/mL for 
cortisol and cortisone, and 1–120 ng/mL for tetrahydrome-
tabolites, with >89 % recovery for all analytes. the coeffi-
cient of variation and accuracy was <10 %, and 85–105 %, 
respectively. Our LC–mS/mS method is accurate and 
reproducible in accordance with Food and Drug admin-
istration guidelines, showing good sensitivity and recov-
ery. this method allows the assessment of 11β-hSD2 and 
11β-hSD1 activities in a single analytical run providing an 
innovative tool to explain etiology of misclassified essential 
hypertension and/or metabolic syndrome.
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Introduction
Cortisol homeostasis is important in controlling blood pres-
sure, and its deregulation could be implied in hypertension 
and metabolic syndrome (metS). Several enzymes modu-
late cortisol availability. In the liver and adipose tissue, 
11β-hydroxysteroid dehydrogenase type 1 (11β-hSD1) 
preferentially converts the inactive cortisone to active corti-
sol. In the kidney and colon, 11β-hydroxysteroid dehydro-
genase type 2 (11β-hSD2) transforms cortisol to cortisone, 
protecting the mineralocorticoid receptor from erroneous 
activation by cortisol. Furthermore, in the liver, the 5α 
and 5β reductases (in conjunction with 3α-hydroxy steroid 
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dehydrogenase) inactivate cortisol and cortisone to the tet-
rahydrometabolites: 5α tetrahydrocortisol, 5β tetrahydro-
cortisol (allo-tetrahydrocortisol), and tetrahydrocortisone 
[1]. thus, the availability of cortisol to bind and activate 
the glucocorticoid and mineralocorticoid receptors may be 
influenced by both the local pre-receptor metabolism and 
the systemic cortisol level.
Based on the functions of the 11β-hSD isozymes, the 
impairment of their activity has been associated with the 
pathogenesis of arterial hypertension and metS, which are 
common medical conditions. assessing the enzymes’ activ-
ities is critical to the study of these patients, where the uri-
nary cortisol/cortisone ratio has been suggested as an index 
of 11β-hSD2 activity. In the presence of a normal cortisol/
cortisone ratio, the ratio of the urinary metabolites tetrahy-
drocortisol and allo-tetrahydrocortisol to tetrahydrocorti-
sone provides an estimate of 11β-hSD1 activity [1, 2].
the steroid hormones in body fluids are usually meas-
ured by immunoassay in the clinical laboratory due to the 
simplicity, speed, and analytical sensitivity. this is possi-
ble using automated analyzers that allow high-throughput 
testing [3]. Despite their many advantages, immunoassays 
have certain limitations, including the differences between 
compounds cross-reactivity that are structurally related to 
the target, suboptimal specificity, limited dynamic range, 
and matrix effects [4]. alternative techniques, such as the 
combination of gas chromatography and mass spectrometry 
(GC–mS), previously the ‘gold standard’ for steroid profil-
ing, are laborious and time consuming due to the low vola-
tility of some compounds and the need of a derivatization 
step, limiting their application to routine diagnostics [5]. 
high-performance liquid chromatography in combination 
with tandem mass spectrometry (LC–mS/mS) fulfills the 
requirements of sufficient analytical sensitivity and speci-
ficity, as well as speed and robustness, for single-steroid 
analysis [6, 7].
the aim of this study was to develop and validate an 
LC–mS/mS method, using uS Food and Drug administra-
tion (FDa) parameters for the simultaneous determination 
of free cortisol, cortisone, tetrahydrocortisol, allo-tetrahy-
drocortisol and tetrahydrocortisone in a clinical laboratory 




all solvents (methanol, acetone, hexane, and water) were 
high-performance liquid chromatography (hPLC) grade 
from merck (Santiago, Chile). Formic acid (merck) was 
98–100 % pure. Cortisol (4-pregnen-11β, 17, 21-triol-3, 
20-dione), cortisol-D4 (4-pregnen-11β, 17, 21-triol-
3, 20-dione-9, 11, 12, 12-d4), cortisone (4-pregnen-17, 
21-diol-3, 11, 20-trione), tetrahydrocortisol (5β-pregnan-
3α, 11β, 17, 21-tetrol-20-one), allo-tetrahydrocortisol 
(5α-pregnan-3α, 11β, 17, 21-tetrol-20-one), and tetrahydro-
cortisone (5β-pregnan-3α, 17, 21-triol-11-20-dione) were 
purchased from Steraloids, Inc., (andover, ma, uSa). 
Stock solutions of all standards (1 mg/mL) and of cortisol-
D4 as the internal standard (IS; 2 μg/mL) were prepared in 
methanol and stored at −20 °C.
Liquid Chromatography
the liquid chromatography separations were carried out 
using an agilent technologies Series 1200 high-pressure 
mixing pump equipped with a Series 1200 autosampler and 
microwell plate autosampler (agilent, Boston, ma, uSa). 
an Inertsil ODS-3 C18 (2.1 mm inner diameter × 150 mm) 
3-μm particle size column (GL Sciences Inc., tokyo, 
Japan) was used with a mobile phase gradient of solvent a 
(water containing 0.1 % formic acid) and solvent B (metha-
nol containing 0.1 % formic acid). the gradient conditions 
were 0–5 min with 40 % solvent a and 60 % solvent B, 
from 6 to 8 min 50 % solvent a and 50 % solvent B, from 
9 to 10 min 60 % solvent a and 40 % solvent B, from 11 to 
13 min 10 % solvent a and 90 % solvent B, and from 14 to 
18 min 40 % solvent a and 60 % solvent B.
mass Spectrometry
an aB Sciex Qtrap® 4500 tandem mass spectrometer 
(Foster City, Ca, uSa) operated with a turbo-V IonSpray 
source was used to obtain the mass spectra and the selected 
reaction monitoring (Srm) determinations. the optimized 
conditions were as follows: ion spray voltage, 5.5 kV; gas 
source 1, 60; gas source 2, 40; turbo temperature, 600 °C; 
entrance potential, 10 V; and declustering potential (DP), 
60 V. the collision gas pressure was set at 12 mPa and the 
curtain gas pressure at 20 mPa. the Srm transitions and 
the related optimized DP, collision energy, and collision 
cell exit potential for the different analytes are shown in 
table 1.
Standards and Quality Control Samples
Working solutions of eight standards (0.1, 1, 5, 10, 30, 60, 
90 and 120 ng/mL) and three quality control samples (QCs; 
20, 40 and 80 ng/mL) were prepared in 1 mL steroid-free 
urine by dilution of the stock solution of each analyte. the 
standards were prepared on the day of analysis, and the 
QCs were prepared in bulk monthly and stored at −20 °C.
the standards and QCs were spiked with 10 μL IS 
(cortisol-D4; 20 μg/mL in methanol; final concentration, 
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20 ng/mL). Before analysis, steroids were extracted on 
SPE columns (Oasis® hLB 3 mL, 60 mg) preconditioned 
sequentially with 3 mL methanol and 3 mL water, followed 
by the addition of 1 mL urine to the columns. the columns 
were washed sequentially with 3 mL water, 3 mL acetone/
water (200 mL/L), and 1 mL hexane. after the columns 
were dried by suction for 2 min, the steroids were eluted 
with 2 mL methanol. the extracts were dried under nitro-
gen and dissolved in 100 μL methanol/water (1:1) contain-
ing 0.1 % formic acid, and 10 μL samples were injected in 
the LC–mS/mS system.
method Validation
the method was validated according to the FDa param-
eters [8]. the linearity was evaluated by the regression 
analysis of standards over the concentration range of the 
calibration curve. the lower limit of detection (LLOD) 
was defined as the lowest concentration of each analyte 
that could be reliably differentiated from background noise 
assessed with a blank sample; the lower limit of quantifica-
tion (LLOQ) was defined as the lowest concentration that 
could be measured with an interday coefficient of variation 
(CV) of <20 % and accuracy between 80 and 120 %.
the precision and accuracy were assessed using the 
three QCs. the QCs were assayed five times within the 
same day for the determination of intraday precision and 
on five consecutive days in duplicate to determine interday 
precision, and the CV was calculated. the CV determined 
at each concentration level should not exceed 15 %. the 
accuracy was defined as the percentage of the nominal con-
centration and was estimated based on the percent devia-
tion of the mean value from the target following five meas-
urements of each of the three QCs. the mean value should 
be within 15 % of the actual value. Calibration curves were 
prepared on each day of analysis.
the matrix effect (mE), recovery (rE), and process 
efficiency (PE) for each analyte were assessed using post-
extraction addition, established by matuszewski et al. [9] 
and others. Briefly, three sets of standards (20, 40 and 
80 ng/mL) were prepared. Set a contained the standard 
and IS in methanol; set B contained extracts spiked with 
the standards and IS after extraction; and set C contained 
regular samples (i.e., urine spiked with the standards and IS 
before extraction). the peak area for the standards in these 
three sets was used to calculate mE, rE, and PE for each 
analyte according to the following equations:
  where A = peak area of each analyte from set a; B = peak 
area of each analyte from set B; and C = peak area of each 
analyte from set C.
Results
LC–mS/mS Characteristics
the method described here allows the detection and quan-
tification of the five free steroids in one analytical run of 
18 min, with good resolution of each analyte. the retention 
times for cortisone, cortisol-D4, cortisol, allo-tetrahydro-
cortisol, tetrahydrocortisol, and tetrahydrocortisone were 
6.53, 8.00, 8.02, 13.02, 13.80, and 14.61 min, respectively. 
a representative mass chromatogram of a physiological 
human urine sample is shown in Fig. 1.
Linearity, Lower Limit of Detection, Lower Limit 
of Quantification, Precision, and accuracy
the assay was linear from 0.1 to 120 ng/mL for cortisol 
and cortisone, and from 1 to 120 ng/mL for tetrahydrocor-
tisol, allo-tetrahydrocortisol and tetrahydrocortisone. the 
regression coefficient (r2) was >0.999 for each of the five 
analytes. LLOD was 0.05 ng/mL for cortisol and cortisone, 
Matrix effect (%) = B/A × 100
Recovery (%) = C/B × 100
Process efficiency (%) = C/A × 100
Table 1  LC/mS–mS data for the corticosteroids studied
a
 Quantitative ions are underlined
b
 Internal standard
Steroid molecular  
weight (Da)








Cortisol 362.21 363.25 327/309/121 80/85/82 21/24/36 16/14/10
Cortisone 360.19 361.24 343/301/163 110/100/75 23/29/33 08/12/12
tetrahydrocortisol 366.24 331.27 313/301/295 95/100/100 17/17/17 13/08/16
allo-tetrahydrocortisol 366.24 331.27 313/295/271 95/75/80 17/18/18 13/16/15
tetrahydrocortisone 364.22 347.28 329/311/243 105/107/110 19/21/30 16/18/13
Cortisol-D4b 366.23 367.27 331/273/121 85/85/85 24/24/36 14/14/10
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Cortisol-D4 peak at 7.87 min Cortisone peak at 6.32 min 
Allo-tetrahydrocortisol peak at 12.88 min Cortisol peak at 7.90 min 
Tetrahydrocortisol peak at 13.62 min Tetrahydrocortisone peak at 14.49 min
Fig. 1  Physiological human sample urine with five steroids and internal standard. Cortisone peak at 6.32 min, cortisol-D4 peak at 7.87 min, 
cortisol peak at 7.90 min, allo-tetrahydrocortisol peak at 12.88 min, tetrahydrocortisol peak at 13.62 min, tetrahydrocortisone peak at 14.49 min






 Coefficient of variation
Steroid QCa 20 ng/mL QCa 40 ng/mL QCa 80 ng/mL
mean 
(ng/mL)










SDb CVc (%) accuracy 
(%)
Cortisol intraday 20.58 0.58 2.81 102.9 39.80 1.00 2.52 99.5 83.47 1.09 1.31 104.34
Interday 20.14 1.47 7.30 100.71 40.04 0.82 2.04 100.10 79.73 6.69 8.39 99.67
Cortisone intraday 19.90 0.86 4.31 99.5 38.63 0.87 2.25 96.6 80.34 5.07 6.31 100.43
Interday 20.86 1.89 9.04 104.32 38.44 1.24 3.23 96.10 80.16 6.84 8.53 100.20
tetrahydrocortisol 
intraday
20.18 1.04 5.14 100.9 38.15 1.86 4.87 95.4 76.99 5.42 7.05 96.23
Interday 17.12 0.34 2.00 85.60 39.94 1.61 4.03 99.85 75.85 5.62 7.41 94.81
allo-tetrahydrocortisol 
intraday
18.22 1.38 7.55 91.1 35.60 1.44 4.04 89.0 73.12 2.68 3.67 91.40
Interday 17.18 0.91 5.33 85.90 38.86 1.75 4.50 97.15 77.21 7.43 9.62 96.51
tetrahydrocortisone 
intraday
19.20 0.65 3.39 96.0 37.03 1.72 4.64 92.6 77.75 5.32 6.84 97.19
Interday 17.94 0.99 5.53 89.70 39.46 1.56 3.95 98.65 79.69 6.56 8.23 99.62
641Simultaneous Determination of Free Urinary Steroids
1 3
and 0.2 ng/mL for allo-tetrahydrocortisol, tetrahydrocorti-
sol and tetrahydrocortisone, and the lowest concentration 
matching the LLOQ acceptance criteria was 0.1 ng/mL for 
cortisol and cortisone and 1.0 ng/mL for allo-tetrahydro-
cortisol, tetrahydrocortisol and tetrahydrocortisone.
the QCs for all five analytes had acceptable intraday 
and interday precision (<10 %) and accuracy (85–105 %); 
these results are shown in table 2.
matrix Effect, recovery, and Process Efficiency
For all analytes, the mean analytical recovery was >89 %, 
with a matrix effect ranging from 90 to 122 % and a pro-
cess efficiency >76 % (table 3).
Discussion
We developed an analytical LC–mS/mS method for the 
determination of five steroids in a single analytical run that 
is reliable, accurate, and precise. Based on FDa regulatory 
guidelines [8], this method is suitable to be implemented 
in a clinical laboratory for routine diagnostic purposes. the 
assay achieved good analytical separation of all five ster-
oids with an acceptable intraday and interday precision and 
accuracy. the ability to measure the five analytes over a 
wide analytical range, from 0.1 to 120 ng/mL for cortisol 
and cortisone, and 1–120 ng/mL for tetrahydrometabolites, 
makes this method well suited for the evaluation of 11β-
hSD1 and 11β-hSD2 activity. this dynamic range broadly 
covers the reference values reported previously by our 
group [1].
recovery and performance efficiency evaluation using 
matuszewski et al. [9] procedure showed that good results 
were achieved for all the five steroids. assessment of mE 
is mandatory in the validation of a quantitative assay using 
LC–mS/mS in biological samples, since endogenous 
impurities can affect the ionization process and may reduce 
or increase the efficiency of formation of the desired ana-
lyte ions. In this way, mE affects assay reproducibility and 
accuracy. Our study documented the absence of a signifi-
cant mE, being allo-tetrahydrocortisol the one that had the 
largest one with a mean enhancement of 22 %. this could 
be caused by the fact that for tetrahydrometabolites the pat-
tern of fragmentation is quite complicated, giving rise to 
spectra containing a large number of fragments which most 
of them are common to several steroid compounds [10]. For 
these reasons, it is necessary to separate the three tetrahy-
drometabolites in a successful chromatographic run prior 
to subsequent mS measurement. Because, in our method, 
allo-tetrahydrocortisol is the analyte with the least analyti-
cal sensitivity, it is the analyte that will be most affected by 
any loss of sensitivity and selectivity.
the use of positive or negative ionization mode was 
evaluated by Cuzzola et al. [11] in the only report in lit-
erature that describes the measurement of the same five 
steroids in human urine in a single analytical run. In this 
paper, the negative mode was selected for further frag-
mentation and quantification of the compounds. this 
approach was used by turpeinen et al. [12], although this 
group measured only tetrahydrometabolites, and also by 
Pavlovic et al. [13] who were able to measure all five ster-
oids but the method was validated in bovine urine. In our 
study, all the results were generated in positive ion mode 
and achieved a good LLOQ of 0.1 ng/mL for F and E, and 
1 ng/mL for the tetrahydrometabolites, although it has 
been reported that the negative ion mode produces better 
signal-to-noise ratio and reduced fragmentation than the 
positive ion mode [11]. Other groups have used the posi-
tive ion mode to measure cortisol and cortisone and their 
tetrahydrometabolites but were unable to separate the iso-
mers tetrahydrocortisol and allo-tetrahydrocortisol [10, 
14]; only Yamashita et al. [15] accomplish this issue but 
their method needs picolinyl derivation of cortisol and cor-
tisone a ring metabolites.
the LLOQ achieved in our work for free steroids meas-
urement is relevant because in urine, only a small fraction 
of the steroids are in the free form, with the larger fraction 
being conjugated to glucuronides and sulfates. the advan-
tage of measuring free steroids is that there is no need to 
deconjugate the urine samples, which is time consuming 
and can increase the chance of inaccurate results due to 
incomplete hydrolysis and variability in the enzyme prepa-
rations [10].
Table 3  matrix effect, recovery 









Steroid mEa (%) rEb (%) PEc (%)
mean SDd mean SDd mean SDd
Cortisol 91.4 16.1 101.3 8.9 91.9 9.3
Cortisone 94.5 19.6 104.5 9.4 98.9 17.9
tetrahydrocortisol 76.9 14.4 99.6 9.4 75.5 14.3
allo-tetrahydrocortisol 122.2 28.5 95.6 9.4 115.5 17.9
tetrahydrocortisone 90.0 16.7 105.2 6.0 94.5 13.3
Cortisol-D4 95.5 7.3 90.0 7.8 85.0 0.9
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the simultaneous measurement of cortisol, cortisone, 
tetrahydrocortisol, allo-tetrahydrocortisol, and tetrahydro-
cortisone will be useful in clinics and, in particular, con-
tribute to a better understanding of the pathophysiology of 
essential arterial hypertension and/or metS. the measure-
ment of clinical diagnostic biomarkers should be reliable, 
robust, and suitable for high-throughput analysis. Since 
its introduction as a highly specialized analytical tool, 
LC–mS/mS has evolved into an accepted, routine diag-
nostic technique in the clinical laboratory. LC–mS/mS is 
now considered the method of choice for the measurement 
of steroid hormones, particularly ones that circulate at low 
concentrations in plasma and/or urine.
Conclusions
the LC–mS/mS method described here is accurate, precise 
and is in accordance with FDa guidelines. Good sensitiv-
ity, rE, and mE were obtained for the simultaneous meas-
urement of the five analytes.
the analytical characteristics of this method make it 
suitable for implementation as a routine technique in the 
clinical laboratory, allowing the assessment of 11β-hSD1 
and 11β-hSD2 activities in a single analytical run.
an adequate clinical endocrinological exam followed 
by the LC–mS/mS analysis of these steroids and accurate 
interpretation of data should aid physicians in identifying 
the etiology of misclassified essential hypertension and/or 
metS.
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